Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Name:	us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT (Details Textual) - AUD	1 Months Ended
	Mar. 31, 2014	Sep. 30, 2017	Dec. 31, 2016
Other Current Assets [Member] \| Research Tax Credit Carryforward [Member]
Research And Development Disclosure [Line Items]
Tax Credit Carryforward, Amount		AUD 18,000	AUD 84,000
Lipimetix Australia Pty Ltd [Member] \| Maximum [Member]
Research And Development Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent	45.00%
Lipimetix Australia Pty Ltd [Member] \| Minimum [Member]
Research And Development Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent	43.50%